Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

584 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
Milgrom SA, Jauhari S, Plastaras JP, Nieto Y, Dabaja BS, Pinnix CC, Smith GL, Allen PK, Lukens JN, Maity A, Oki Y, Fanale MA, Nasta SD. Milgrom SA, et al. Among authors: oki y. Cancer. 2017 Apr 15;123(8):1363-1371. doi: 10.1002/cncr.30482. Epub 2016 Dec 16. Cancer. 2017. PMID: 27984652 Free PMC article.
Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Oki Y, Ogura M, Kato H, Kikuchi A, Taji H, Kagami Y, Oshiro A, Tsujimura A, Yamamoto K, Morishima Y. Oki Y, et al. Cancer Sci. 2008 Jan;99(1):179-84. doi: 10.1111/j.1349-7006.2007.00662.x. Epub 2007 Nov 7. Cancer Sci. 2008. PMID: 17991293 Free PMC article. Clinical Trial.
Favorable consolidative effect of high-dose melphalan and total-body irradiation followed by autologous peripheral blood stem cell transplantation after rituximab-containing induction chemotherapy with in vivo purging in relapsed or refractory follicular lymphoma.
Kato H, Taji H, Ogura M, Kagami Y, Oki Y, Tsujimura A, Fuwa N, Kodaira T, Seto M, Yamamoto K, Morishima Y. Kato H, et al. Among authors: oki y. Clin Lymphoma Myeloma. 2009 Dec;9(6):443-8. doi: 10.3816/CLM.2009.n.087. Clin Lymphoma Myeloma. 2009. PMID: 19951884
584 results